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A B S T R A C T
Background
Tracheomalacia, a disorder of the large airways where the trachea is deformed or malformed during respiration, is commonly seen in
tertiary paediatric practice. It is associated with a wide spectrum of respiratory symptoms from life-threatening recurrent apnoea to
common respiratory symptoms such as chronic cough and wheeze. Current practice following diagnosis of tracheomalacia includes
medical approaches aimed at reducing associated symptoms of tracheomalacia, ventilation modalities of continuous positive airway
pressure (CPAP) and bi-level positive airway pressure (BiPAP), and surgical approaches aimed at improving the calibre of the airway
(airway stenting, aortopexy, tracheopexy).
Objectives
To evaluate the efficacy of medical and surgical therapies for children with intrinsic (primary) tracheomalacia.
Search methods
TheCochrane AirwaysGroup searched theCochraneCentral Register of ControlledTrials (CENTRAL), theCochrane AirwaysGroup’s
Specialised Register, MEDLINE and EMBASE databases. The Cochrane Airways Group performed the latest searches in March 2012.
Selection criteria
All randomised controlled trials (RCTs) of therapies related to symptoms associated with primary or intrinsic tracheomalacia.
Data collection and analysis
Two reviewers extracted data from the included study independently and resolved disagreements by consensus.
Main results
We included one RCT that compared nebulised recombinant human deoxyribonuclease (rhDNase) with placebo in 40 children with
airway malacia and a respiratory tract infection. We assessed it to be a RCT with overall low risk of bias. Data analysed in this review
showed that there was no significant difference between groups for the primary outcome of proportion cough-free at two weeks (odds
ratio (OR) 1.38; 95% confidence interval (CI) 0.37 to 5.14). However, the mean change in night time cough diary scores significantly
favoured the placebo group (mean difference (MD) 1.00; 95% CI 0.17 to 1.83, P = 0.02). The mean change in daytime cough diary
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scores from baseline was also better in the placebo group compared to those on nebulised rhDNase, but the difference between groups
was not statistically significant (MD 0.70; 95% CI -0.19 to 1.59). Other outcomes (dyspnoea, and difficulty in expectorating sputum
scores, and lung function tests at two weeks also favoured placebo over nebulised rhDNase but did not reach levels of significance.
Authors’ conclusions
There is currently an absence of evidence to support any of the therapies currently utilised for management of intrinsic tracheomalacia.
It remains inconclusive whether the use of nebulised rhDNase in children with airway malacia and a respiratory tract infection worsens
recovery. It is unlikely that any RCT on surgically basedmanagement will ever be available for childrenwith severe life-threatening illness
associated with tracheomalacia. For those with less severe disease, RCTs on interventions such as antibiotics and chest physiotherapy
are clearly needed. Outcomes of these RCTs should include measurements of the trachea and physiological outcomes in addition to
clinical outcomes.
P L A I N L A N G U A G E S U M M A R Y
Interventions for primary (intrinsic) tracheomalacia in children
The term malacia is derived from the Greek word ’malakia’, meaning soft. In tracheomalacia, the walls of trachea (or windpipe) are
softer than normal, which can lead to partial collapse (falling in) of the windpipe. This collapse usually happens when more air is
needed, such as during exercise. The word ’primary’ refers to tracheomalacia in which the windpipe itself is the cause of the disease,
where as secondary tracheomalacia is compressed due to some other abnormality near to the windpipe. The most common symptom of
tracheomalacia is expiratory stridor (high-pitched wheezing sound). If the symptoms are severe enough, treatment such as mechanical
ventilation, tracheal stenting (mesh tube inserted into windpipe to hold it open) or surgery may be needed.
We wanted to find out which out of these possible treatments was most effective. We found only one randomised controlled trial
(RCT) that assessed nebulised recombinant human deoxyribonuclease (rhDNase) which helps in breaking down the mucous and has
been shown to be useful in aiding airway clearance in cystic fibrosis compared to placebo (no active treatment) in children with both
tracheomalacia and a concurrent respiratory infection. This trial showed no evidence of benefit in terms of the number of children who
were cough-free two weeks after treatment. Also, there was less coughing reported, both during the day and at night, in the group who
did not receive the intervention - however these differences were not statistically significant.
With the lack of evidence, the routine use of any therapies for intrinsic tracheomalacia cannot be recommended given the cost of
nebulised rhDNase and the likely harmful effect. The decision to subject a child to any surgical or medical based therapies will have to
be made on an individual basis, with careful consideration of the risk-benefit ratio for each individual situation.
It is unlikely that any RCT on surgically based management will ever be available for children with severe life-threatening illness
associated with tracheomalacia. For those with less severe disease, RCTs on interventions such as antibiotics and chest physiotherapy
are needed.
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B A C K G R O U N D
Tracheomalacia is a disorder of the large airways where the tra-
chea is deformed ormalformed during respiration (Masters 2002).
Tracheomalacia is commonly seen in tertiary paediatric practice
(Masters 2002) and many of the children are only referred for as-
sessment after repeated failure of therapies, which include asthma
drug therapies (Gormley 1999; Thomson 2002). This large air-
way disorder can be classified as primary (intrinsic abnormality
of the airway) or secondary (related to compression of trachea by
another structure such as a mass). Primary tracheomalacia may
occur in isolation, or in association with other malacia disorders
(laryngomalacia and bronchomalacia), as part of a syndrome (e.g.
Downs syndrome, Ehlers-Danlos syndrome), or with other con-
genital non-syndromic disorders (e.g. cardiac abnormalities, tra-
cheoesophageal fistula etc.) (Austin 2003; Masters 2002). Some
have classified tracheomalacia associated with other abnormali-
ties as secondary tracheomalacia assuming that it is related to the
compression effects. Embryologically, these tracheomalacia are re-
lated to a developmental abnormality with the associated condi-
tion (as opposed to because of the associated condition) (Beasley
1998) and in general do not totally resolve after correction of the
associated problem (such as in tracheoesophageal fistula (Kovesi
2004) or after thoracic vascular surgery (Horvath 1992; van Son
1993). Therefore we have classified these types of tracheomala-
cia as primary tracheomalacia with associated abnormalities. True
secondary tracheomalacia generally resolves on removal of the of-
fending agent (such as a mediastinal mass or lymph node) and
thus will not be discussed in this review.
Description of the condition
Tracheomalacia is associated with common respiratory symptoms
(Masters 2009). The most common symptoms at presentation are
persistent respiratory symptoms, in particular chronic cough and
wheeze. These symptoms cover most of the common respiratory
symptoms seen in children and thus it not surprising that diagno-
sis is often delayed (Gormley 1999; Masters 2002; Wood 1997).
Gormley 1999 described that 75% of childrenwith congenital tra-
cheomalacia secondary to congenital vascular anomaly had persis-
tent cough at presentation. As these symptoms overlap with other
respiratory disorders, it is also not surprising that the diagnosis
and management of tracheomalacia is often suboptimal (Gormley
1999). Other respiratory symptoms include recurrent infections
and pneumonia, recurrent cyanosis, stridor, exertional dyspnoea
and effort intolerance. Severe tracheomalacia may also be associ-
ated with difficult anaesthesia (Austin 2003) and increased CO2
value during flexible bronchoscopy under general anaesthesia is
associated with these airway lesions (Chang 2004). Non-respira-
tory symptoms related to tracheomalacia have also been described
and these include dysphagia (Agrawal 1999) and gastroesophageal
reflux (Bibi 2001).
Tracheomalacia may be diagnosed by flexible and rigid bron-
choscopy, radiological airway screening, chest computed tomog-
raphy (CT) scan, magnetic resonance imaging (MRI) or tracheo-
bronchogram. The current gold standard of diagnosing tracheo-
malacia is by visual assessment during bronchoscopy (Wright
2003) and flexible bronchoscopy is superior to rigid bronchoscopy
for evaluation of tracheobronchomalacia (Midulla 2003). Airway
screening is a rather insensitive tool for diagnosis of tracheoma-
lacia in children (Sanchez 2012). Flexible bronchoscopy provides
the best assessment for the dynamic airway changes found in tra-
cheobronchomalacia (Midulla 2003). The other methods of di-
agnosis are less reliable and/or have major pitfalls. During flexible
bronchoscopy, different visual descriptions of tracheomalacia have
been described (Masters 2002). However the associated symptoms
are similar (Masters 2002).
Description of the intervention
The respiratory symptoms attributed to tracheomalacia are most
likely primarily to be related to the effect of a narrowed airway
generating altered airflow. Wheeze is generated from altered flow
through a narrowed tube. Misdiagnosis of asthma in children with
airway malacia disorders has been well described (Finder 1997).
Cough is likely related to reduction of mucociliary clearance as the
compressed airway impedes clearance of secretions (Finder 1997)
which sets up a bronchitic process distal to the lesion. Exactly
why this occurs is unknown but the possibility of a more subtle
process that involves functional abnormalities in the development
of the neurovascular and airway immunological, smooth muscle
and epithelial cell lines would be biologically possible, but have
not been described. Thus, it is also plausible that a change in
anatomical improvement (if possible) may not necessary result in
symptomatic improvement.
Thus, interventions for tracheomalacia include: procedures or
medications that improve airway calibre (such as stents, aortopexy
and continuous positive airway pressure), enhance airway clear-
ance (such as mucoactive agents like hypertonic saline and nebu-
lised recombinant human deoxyribonuclease (rhDNase)), short-
and/or long-term antibiotics to treat and/or prevent infective ex-
acerbations and reduce airway inflammation (such as corticos-
teroids).
How the intervention might work
Current practice following diagnosis of tracheomalacia includes
medical approaches aimed at reducing associated symptoms of tra-
cheomalacia and surgical approaches aimed at improving the cal-
ibre of the airway (airway stenting, aortopexy) and thus reducing
associated symptoms.
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Why it is important to do this review
Children with tracheomalacia often have respiratory symptoms,
and it is not an uncommon disease among children (incidence
of approximately 1 in 1500 to 2500 children in a study in The
Netherlands) (Boogaard 2005). The interventions described above
may have serious and significant adverse events. Hence, there is a
need for systematic evaluation of the effects of interventions aimed
at reducing the respiratory symptoms related to tracheomalacia.
O B J E C T I V E S
To evaluate the efficacy of medical and surgical therapies for chil-
dren with intrinsic (primary) tracheomalacia.
M E T H O D S
Criteria for considering studies for this review
Types of studies
All randomised controlled trials (RCTs) of therapies related to
symptoms associated with primary or intrinsic tracheomalacia.
Types of participants
Children aged < 15 years with tracheomalacia with associated res-
piratory symptoms.
Exclusion criteria: secondary tracheomalacia.
Types of interventions
All randomised controlled comparisons of therapies for symptoms
associated with primary or intrinsic tracheomalacia. We included
trials that included the use of other medications or interventions
if all participants had equal access to such medications or inter-
ventions.
Types of outcome measures
Primary outcomes
1. Proportion of participants who were not cured or not
substantially improved at follow-up (clinical failure).
Secondary outcomes
1. Proportion of participants who were not cured at follow-up.
2. Proportion of participants who not substantially improved
at follow-up.
3. Mean difference (MD) in number of respiratory episodes
(defined by diary cards or acute respiratory illness score).
4. Proportion requiring hospitalisation for respiratory illness.
5. MD in symptoms and signs (mean improvement in clinical
state).
6. Proportion developing new respiratory complications such
as bronchiectasis, bronchiolitis obliterans, etc.
7. Proportion requiring acute or complicated airway
intervention (prolonged intubation, tracheostomy, etc.).
8. Proportion experiencing adverse effects of the intervention
(e.g. death from surgery, surgical complications, etc.).
The proportion of participants who failed to improve on treatment
and the mean clinical improvement were to be determined using
the following hierarchy of assessment measures (i.e. where two
or more assessment measures are reported in the same study, the
outcomemeasure that is listed first in the hierarchywould be used).
1. Objective measurements of cough indices (cough
frequency).
2. Symptomatic (Quality of life scale, Likert scale, visual
analogue scale (VAS), level of interference of respiratory
symptoms such as cough, wheeze, cyanotic events, etc. using
diaries) - assessed by child.
3. Symptomatic (Quality of life scale, Likert scale, VAS, level
of interference of respiratory symptoms such as cough, wheeze,
cyanotic events, etc. using diaries) - assessed by the parents/carers.
4. Symptomatic (Likert scale, VAS, level of interference of
respiratory symptoms such as cough, wheeze, cyanotic events,
etc. using diaries) - assessed by clinicians.
5. Pulmonary function tests.
6. Bronchoscopic assessment of tracheomalacia (using flexible
bronchoscopy).
7. Relevant airway markers consistent with neutrophillic
inflammation.
Search methods for identification of studies
Electronic searches
We used the following topic search strategy to identify the rele-
vant randomised controlled trials (RCTs) listed in the electronic
databases.
(“ tracheomalacia ” OR “ tracheo-malacia ” OR “malacia” OR “
trachea abnormalities” OR “tracheal diseases” all as (text word) or
(MeSH)) AND (“child” OR “children”OR “infant” as (text word)
or (MeSH)). The full search strategies are shown in Appendix
1; Appendix 2; and Appendix 3. We identified trials from the
following sources.
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1. The Cochrane Controlled Trials Register (CENTRAL),
which includes the Cochrane Airways Review Group’s
Specialised Trials Register, Issue 2 of 12, 2012.
2. MEDLINE 1946 to March 2012.
3. EMBASE 1980 to March 2012.
We did not impose any restriction on language of publication, or
publication status. We conducted the searches in March 2012.
Searching other resources
In addition, we searched the list of references in relevant publica-
tions and wrote to authors of trials included in the review.
Data collection and analysis
Selection of studies
From the title, abstract or descriptions, two authors independently
reviewed literature searches to identify potentially relevant trials
for full review. We searched bibliographies and texts to identify
additional studies (IBM and AC in the original review and VG
and AC in this updated review. From the full-text using specific
criteria, VG and AC independently selected trials for inclusion.
Disagreement would have been resolved by consensus, but there
was no disagreement between the two authors.
Data extraction and management
We reviewed the trials that satisfied the inclusion criteria and
recorded the following information: study setting; year of study;
source of funding; patient recruitment details (including number
of eligible children); inclusion and exclusion criteria; randomisa-
tion and allocation concealment method; numbers of participants
randomised; blinding (masking) of participants; care providers
and outcome assessors; intervention (duration and type); control;
co-morbidities (all medical problems with particular attention to
genetic syndromes and co-morbidities); existing respiratory prob-
lems; cointerventions; numbers of patients not followed up; rea-
sons for withdrawals from study protocol (clinical, side effects,
refusal and other), details on side effects of therapy; and whether
intention-to-treat analyses were possible. We had planned to ex-
tract data on the outcomes described previously.
We extracted information from the study for the following char-
acteristics.
1. Type of study (description of randomisation, blinding,
allocation, withdrawals).
2. Participants (N, age range).
3. Intervention (type of intervention: medical or surgical,
duration of intervention, cointerventions).
4. Outcomes (primary and secondary outcomes, timing of
outcome assessments, adverse outcomes).
We planned to request further information from the trial authors
where required. Dr Boogaard (Boogaard 2009) kindly provided
us with his raw data that enabled us to calculate the number of
participants who failed to improve at the end of two weeks.
Assessment of risk of bias in included studies
We assessed risk of bias in the trials for the following seven domains
using the ’Risk of bias’ table inReviewManager 5 (RevMan 2011).
The authors judged whether there was high or low risk of these
biases. Where the risk was not clear, we stated as such.
1. Sequence generation.
2. Allocation concealment.
3. Blinding of participants and personnel.
4. Blinding of outcome assessment.
5. Incomplete outcome data.
6. Selective reporting.
7. Other potential sources of biases.
Measures of treatment effect
We extracted data for each of the outcomes (where data were
available) from the trial publication that fulfilled the inclusion
criteria.
Unit of analysis issues
We sought to obtain data that were reported with patients (rather
than events) as the unit of analysis for the primary outcomes.
Dealing with missing data
We contacted the authors for missing data. For intention-to-treat
analysis, we assumed that missing values would have had poor
outcomes. We planned to perform sensitivity analyses to assess
how sensitive the results are to the reasonable assumptions made
in regards to the missing data.
Assessment of heterogeneity
We had planned to describe and explore heterogeneity between
the study results and to use the 95% CI, estimated using a ran-
dom-effects model, whenever there were concerns about statistical
heterogeneity.
Assessment of reporting biases
We had planned to identify and report on any selective reporting
in the included trials. We would have tested publication bias using
a funnel plot, if five or more studies were available in the review.
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Data synthesis
We had planned to combine data using Review Manager 5
(RevMan 2011), with a view to using a fixed-effect mean differ-
ence (MD) (calculated as a weighted MD) for continuous data
variables. If different scales were combined, we had intended to
use the standardised mean difference (SMD).
For dichotomous outcome variables of each individual study, we
calculated the odds ratios (ORs) using a modified intention-to-
treat analysis (i.e. failure assumed if participant drops out of study).
This analysis assumes that children not available for outcome as-
sessment have not improved (and probably represents a conserva-
tive estimate of effect).
We intended to calculate a number needed to treat (benefit or
harm) when possible for the different levels of risk as represented
by control group event rates over a specified time period using the
pooled OR and its CI using an online calculator, Visual Rx (Cates
2003). We constructed a ’Summary of findings’ table according
to recommendations in the Cochrane handbook of Systematic
Reviews of Interventions (Higgins 2011).
Subgroup analysis and investigation of heterogeneity
We had planned an a priori subgroup analysis for:
1. age: infants (less than12 months) or children (aged 1 to 14
years);
2. presence of congenital (cardiac, tracheoesophageal fistula)
syndromes;
3. medical therapies; and
4. surgical therapies.
As there was only a single study, a subgroup analysis was not ap-
plicable.
Sensitivity analysis
We had planned sensitivity analyses to assess the impact of the
following potentially important factors on the overall outcomes.
1. Variation in the inclusion criteria.
2. Differences in other medications/procedures used in the
intervention and comparison groups.
3. Analysis using a random-effects model.
4. Analysis by ’treatment received’ or ’intention-to-treat’.
As there was only a single study, a sensitivity analysis was not
applicable.
R E S U L T S
Description of studies
See:Characteristics of included studies; Characteristics of excluded
studies.
Results of the search
The original search in 2008 did not identify any eligible studies.
The Airways Group search in March 2012 identified 118 poten-
tially relevant titles since the last update of the review (2008). After
assessing the abstracts, we retrieved five papers, out of which we
considered only one study for inclusion in the review as it fulfilled
the study eligibility criteria.
Included studies
The single eligible study (Boogaard 2009) was conducted in chil-
dren that had planned to include children aged 2 to 18 years. We
included this study as children were aged 2.8 to 15.5 years. This
RCT compared nebulised recombinant human deoxyribonucle-
ase (rhDNase) with placebo in children with airway malacia and
lower respiratory tract infection (LRTI). The episode of LRTI was
defined by the authors as (an increase in) productive cough or
dyspnoea, and/or auscultatory abnormalities on physical exami-
nation, and/or increased bronchitic markings or consolidation on
a chest radiograph respiratory exacerbation. The primary outcome
of this study was change in cough diary scores(week two compared
to baseline) and this score was a validated scoring system (Chang
1998a). Details of the study are in Characteristics of included
studies and some aspects are also described below. The authors of
the study used the term airway malacia so we have used this term
accordingly along with tracheomalacia.
Excluded studies
We have added one of the more recent non-controlled studies to
Characteristics of excluded studies (Gallagher 2011). Itwas a retro-
spective study (hospital chart review) comparing the treatment re-
sults of ipratropiumbromide in childrenwith tracheomalacia. The
authors reported that 32 out of 52 children (for whom complete
data were available) diagnosed with tracheomalacia and treated
with ipratropium bromide after having been referred for special-
ist care, had improvement in their symptoms following treatment
with ipratropium bromide.
Risk of bias in included studies
Overall we assessed the sole included study (Boogaard 2009) to
have a low risk of bias as detailed in the ’Risk of bias’ table and
summarised in Figure 1. The following ’Risk of bias’ domains refer
to the sole study (Boogaard 2009) included in this review.
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Figure 1. Risk of bias graph: Review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
Allocation
Randomisation was done in the pharmacy using a computer-gen-
erated blocked randomisation list prepared by a statistician. The
study medication was prepared by a hospital pharmacist.
Blinding
Study medication and placebo vials had identical appearance and
smell. The parents, children, pulmonologists and trial co-ordina-
tor remained unaware of the treatment assignment.
Incomplete outcome data
The number of participants withdrawn (one in the placebo group
before the study drugwas given, and one in the nebulised rhDNase
group after the first dose of the study drug) and those who did not
fill in their cough diary scores (one in each group) were reported
for both nebulised rhDNase and placebo groups.
Selective reporting
There was no suggestion that selective reporting had occurred.
Other potential sources of bias
The study was sponsored by pharmaceutical companies but re-
portedly they neither had influence on the design of the study, on
the analysis of the study data nor in the publication of the results.
Effects of interventions
See: Summary of findings for the main comparison
Human deoxyribonuclease versus placebo for primary (intrinsic)
tracheomalacia in children
Primary outcome
The primary outcome for the review was the proportion of partici-
pants who were not cured or not substantially improved at follow-
up (clinical failure). Authors did not define this and hence from
the raw data provided by Dr Boogaard, we calculated the number
of children with clinical failure at follow-up. Based on previous
published studies (Chang 1998b; Chang 2012; Marchant 2012),
we defined clinical failure as less than 75% improvement in aver-
age daytime and night time cough diary scores at two weeks. We
took the average of daytime and night time cough diary scores in
the first two days of the study and compared it with the average of
night time and daytime cough diary scores on day 13 and day 14.
For one participant a cough diary score was not available for day
13 and so we used days 12 and 14 for this calculation. Another
participant had daytime data missing for day 14, and so we used
days 12 and 13 for this estimation. As depicted in (Analysis 1.1),
12 participants out of 21 were not cured or significantly improved
at two weeks in the placebo group, compared to 11 participants
out of 17 in the nebulised rhDNase group. There was no signif-
icant difference between the groups (OR 1.38; 95% CI 0.37 to
5.14; Figure 2).
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Figure 2. Forest plot of comparison: Number of children with clinical failure at 2 weeks.
Secondary outcomes
Change in cough score from baseline
Mean changes in daytime cough diary score (Analysis 1.2) from
baseline was better in the placebo group compared to those on
nebulised rhDNase treatment, but the difference between groups
was not statistically significant (mean difference (MD) 0.70; 95%
CI -0.19 to 1.59). The change in night time scores (Analysis 1.3)
significantly favoured the placebo group (MD 1.00; 95% CI 0.17
to 1.83, P = 0.02; Figure 3).
Figure 3. Forest plot of comparison: Change from baseline in night time cough diary score.
There was a significant (P = 0.02) difference between groups for
visual analogue scores (VAS) of night time cough (Analysis 1.5;
Figure 4) favouring the placebo group (MD 23.00; 95% CI 3.86
to 42.14), but there was no significant difference between groups
for daytime score (Analysis 1.4) (MD 15.70; 95% CI -3.33 to
34.73).
Figure 4. Forest plot of comparison: Change from baseline in night time visual analogue score.
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Need for antibiotics
Antibiotics were started in 5 of 17 (29%) children in the nebulised
rhDNase group and in 8 of 21 (38%) children in the placebo
group during the two week treatment period, (MD 9%; 95% CI
-21% to 39%, P = 0.58).
Other scores
Boogaard 2009 also described VAS for daytime dyspnoea, night
time dyspnoea (Analysis 1.6), and for difficulty in expectorating
sputum (Analysis 1.7). These outcomes all improved significantly
in both the nebulised rhDNase and placebo groups during the
treatment period; the difference between the nebulised rhDNase
and placebo favoured the placebo group, but these differences were
not statistically significant.
Lung function
The forced vital capacity (FVC) percentage predicted improved
significantly in the placebo group but worsened in the nebulised
rhDNase group (Analysis 1.8; Figure 5). The difference between
the groups was at borderline significance (MD8.80; 95%CI -0.05
to 17.80, P = 0.05). The forced expiratory volume in one second
(FEV1) percentage predicted also improved (Analysis 1.9) in the
placebo group as compared to the nebulised rhDNase group, but
there was no significant difference between the groups (MD 9.20;
CI -0.55 to 18.95, P = 0.06; Figure 6).
Figure 5. Forest plot of comparison: Lung Function at end point mean change in FVC % from baseline.
Figure 6. Forest plot of comparison: Lung Function at end point mean change in FEV1 % from baseline.
D I S C U S S I O N
Summary of main results
This reviewupdate is limited to a single study eligible for inclusion.
Nebulised recombinant human deoxyribonuclease (rhDNase) did
not improve and likely worsened respiratory symptoms when used
during lower respiratory tract infections (LRTIs) in children with
airway malacia. The data from this review were different to that
published in the paper as we did not adjust for baseline imbalance.
The children in the nebulised rhDNase group were symptomatic
for seven days as compared to three days for placebo. Also, at
baseline the placebo group showed lower lung function, andhigher
visual analogue scores (VAS) for night time cough and night time
dyspnoea than did the nebulised rhDNase group. There were no
other significant differences between groups at baseline. Hence,
we did not adjust for baseline. The likely harm from nebulised
rhDNase which was found in our review, was not evident in the
published paper after adjusting for baseline (Boogaard 2009).
Boogaard 2009 postulated that dynamic airway collapse during
coughing in childrenwith airwaymalacia results in airway obstruc-
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tion and impaired mucociliary clearance, and expected a beneficial
effect of nebulised rhDNAse during LRTIs. However, we found
the reverse. There are several possible explanations for the lack of
beneficial effect of nebulised rhDNase in this study compared to
that for children with cystic fibrosis (CF). One reason is the differ-
ence between the physical characteristics of mucous produced in
children with CF (in CF large polymers predominate in the airway
secretions; these polymers include deoxyribonucleic acid (DNA),
filamentous actin, proteoglycans, and bio films, which in combi-
nation with bacteria and inflammatory cells constitute sputum)
and children with primary tracheomalacia (Voynow 2009). The
mucous produced in children with airway malacia is likely similar
to normal children. Unlike children with CF, the reduced mucous
clearance in children with airway malacia is likely related to airway
mechanics. The quality of sputum can be measured by different
properties like dynamic viscoelasticity, wettability, cohesivity, in-
terfacial (surface) tension, solids composition, Interleukin 8 and
DNA content (Rubin 2007). The rheologic properties that favour
mucociliary clearance appear to hinder cough clearance and vice
versa (Rogers 2006). Thus the use of nebulised rhDNAse that al-
ters sputum cohesiveness can impair airway clearance. This review
highlights the fact that some of the interventions (like nebulised
rhDNase) advocated by some for use in children with primary tra-
cheomalacia are not efficacious or even potentially harmful. The
non-beneficial and likely harmful effect of nebulised rhDNase we
found in our review is similar to that described in the detrimental
effect of nebulised rhDNase when used in adults with non-CF
bronchiectasis (Crockett 2001).
Overall completeness and applicability of
evidence
For determining the primary outcome in our review, we averaged
the scores over the first two days (for baseline) and the last two days
(for final score). This was done as there is a day to day variability
in cough diary cards and thus taking an average at the start and at
the end (as done in our various studies on cough such as Chang
2010 and Marchant 2012) is arguably more robust. Furthermore,
when we used only the first and last day’s data, the difference in
results of clinical failure remained statistically insignificant.
The single study on nebulised rhDNase cannot be applied to the
effect of othermucolytics for airwaymalacia. This review has high-
lighted the fact that, although there are many medical and surgical
therapies being used for themanagement of children with tracheo-
malacia, there remains a paucity in high quality data to support
any single intervention. Although the review has shown that neb-
ulised rhDNase is not useful as a medical therapy in children with
airway malacia, this review is not a meta-analysis of different types
of treatment options for tracheomalacia as there are no published
RCTs. This review highlights the need to provide evidence based
answers to this query.
Quality of the evidence
There is only a single study in this review and hence quality of
evidence is substantially limited.
Potential biases in the review process
The Cochrane Airways Group conducted an extensive search for
RCTs in children with airway malacia. Two authors independently
screened the searches and identified one study for inclusion. We
identified the study itself as having overall low risk of bias. We
have contacted the original investigators who kindly provided the
raw data for calculation of clinical failure.
Agreements and disagreements with other
studies or reviews
There are numerous cohort descriptive studies with varying num-
bers of patients that reported on a variety of interventions (mainly
surgical) to increase the airway calibre. Most of these children
managed surgically had presumably the severe end of the clini-
cal spectrum, with life-threatening apnoea episodes. These cohort
studies (see Characteristics of excluded studies) have highlighted
the importance of interventions in terms of clinical improvement.
However these surgical procedures (tracheopexy, aortopexy and/
or stenting) are not universally successful and have associated mor-
bidity and mortality (Valerie 2005). Continuous positive airway
pressure (CPAP) alters forced expiratory flow in infants, but the
authors did not describe clinical correlates (Davis 1998). There are
no studies that quantitatively defined severity, either anatomically
or clinically. Also, when tracheomalacia is associated with a vascu-
lar compression, surgical correction of the vascular compression
alleviates major respiratory symptoms in most (68%) but not in a
significant number of children (Benjamin 1976; Bonnard 2003).
Physiological measurement studies of lung function have shown
short-term benefits in function in lung mechanics and improve-
ment in spirometric parameters for selective children managed
with surgical intervention (Zinman 1995) and CPAP (Davis
1998). However there are no quantitative assessments of severity
of the tracheomalacia at the entry or end point. Interpretation of
lung function may be limited unless paired (pre- and post-inter-
vention) data are obtained, as children with these airway abnor-
malities may have reduced lung growth (Agrawal 1999). At the
mild end of the spectrum there are no studies that have assessed
the disease impact, assessed the management of intercurrent res-
piratory illness or symptoms associated with tracheomalacia, nor
supported any treatment for it.
A U T H O R S ’ C O N C L U S I O N S
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Implications for practice
Based on a single randomised trial, it is not possible to makemean-
ingful recommendations for the routine use of any therapies for
intrinsic tracheomalacia. Results of a single trial show that neb-
ulised rhDNase appears not to be efficacious and likely harmful
when used during a respiratory exacerbation. The decision to sub-
ject a child to surgical and/or medical based therapies will have to
be made on an individual basis, with careful consideration of the
risk-benefit ratio for each individual situation.
Implications for research
It is unlikely that any RCT on surgery for children with life-threat-
ening illness associated with tracheomalacia will ever be available.
For those with less severe disease, RCTs on interventions currently
used bymany respiratory physicians such as early use of antibiotics
and chest physiotherapy are clearly needed. Other possible inter-
ventions include different mucolytics (such as hypertonic saline)
and anti-inflammatories such as corticosteroids. Such trials should
be parallel double-blind studies and outcomes should include cor-
relation with measurements of the trachea and physiological based
measurements in addition to clinical outcomes.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Boogaard 2009
Methods • Prospective, double-blind, parallel group randomised controlled study
• Compared effect of inhaled rhDNase with placebo on respiratory symptoms, the
need for antibiotics, and lung function
• Outpatient setting in Erasmus MC-Sophia Children’s Hospital and Amphia
Hospital, Breda between September 2005 and March 2008
• Children already diagnosed with malacia according to accepted guidelines
(described in the study)
• Children with airway malacia and recurrent LRTIs from outpatient department,
were instructed to contact the hospital when they developed symptoms suggestive of a
LRTI
• Patients were recruited by paediatric pulmonologists at the outpatient department
within 2 days of this contact
• Allocation sequence executed by the study co-ordinator based on the
randomisation schedule prepared by the study statistician
• The decision for investigations was up to the paediatric pulmonologist
• Patients were re-evaluated by a paediatric pulmonologist after 1 (visit 2) and 2
weeks (visit 3)
• The study co-ordinator contacted parents by telephone after 3 weeks
Participants • 49 children screened for inclusion
• 5 did not have LRTI and 4 needed antibiotics
• 22 were assigned to the placebo group and 18 to the rhDNase group (total 40)
• 21 children received placebo and 17 children received rhDNase (20 females out of
38); one withdrawal in each group
• Mean age in placebo group was 6.0 and 6.7 years in the rhDNase group. Inclusion
criteria: children aged 2 to 18 years with airway malacia and symptoms of LRTI
• Baseline demographic characteristics did not differ between the treatment groups
• Exclusion criteria: need for antibiotics at initial presentation, chronic
cardiopulmonary disease and neuromuscular disease
Interventions • 2.5 mg of rhDNase (2.5ml solution of 1 mg/mlL rhDNase) or 2.5 mg placebo (2.
5mL sodium chloride 0.9%), twice daily for 2 weeks
• Study medication was administered with a Sidestream jet nebuliser using a
PortaNeb Compressor
• The first dose of study medication was administered in the outpatient department
Outcomes Primary outcomes: change in symptom severity from baseline to second week of treat-
ment, assessed with a cough diary score
Secondary outcomes:
• need for an antibiotic course during the two-week treatment period
• cough scores
• severity of dyspnoea
• ease of expectorating sputum
• lung function
17Interventions for primary (intrinsic) tracheomalacia in children (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Boogaard 2009 (Continued)
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation done in the pharmacy us-
ing a computer-generated blocked ran-
domisation list prepared by statistician
Allocation concealment (selection bias) Low risk The studymedicationwas prepared by hos-
pital pharmacist and rhDNase and placebo
vials had identical appearance and smell
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Throughout the study, parents, children,
pulmonologists and trial co-ordinator re-
mained unaware of the treatment assign-
ment
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Both subjects and researchers were blinded
to the outcomes measured but blinding by
statistical team was not mentioned
Incomplete outcome data (attrition bias)
All outcomes
Low risk No study data was available for one child
from each group as they did not take the
study medication or withdrew after ran-
domisation
Selective reporting (reporting bias) Low risk No evidence of selective reporting found
Other bias Unclear risk Study funded by pharmaceutical compa-
nies but the companies did not have influ-
ence on the design of the study, analysis of
the study data or writing of the manuscript
LRTI: lower respiratory tract infection
rhDNase: recombinant human deoxyribonuclease
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Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Abdel-Rahman 2002 Non-controlled study. Authors reported on effect of aortopexy on 16 infants and children with tracheomala-
cia. No intraoperative or postoperative mortality occurred and 13 (81%) had permanent relief of symptoms
Corbally 1993 Non-controlled study. Authors reported on 48 patients with repaired congenital oesophageal anomaly who
underwent aortopexy for significant tracheomalacia. Indications for aortopexy included recurrent apnoea/
cyanosis, near fatal episodes, recurrent respiratory distress and infection and worsening stridor. Aortopexy
cured near fatal episodes in all patients and resulted in improvement of airway obstruction in 95%. The
procedure failed in 2 patients due to unrecognised bronchomalacia and phrenic nerve palsy
Davis 1998 Non-controlled study. Continuous positive airway pressure (CPAP) was used to minimise airway collapse
in infants with tracheomalacia. Forced expiratory flows increased with CPAP use
Filler 1993 Non-controlled study. The authors reported on their five-year experience of inserting the Palmaz stent into
infants and children who had a variety of major airway obstructions, including tracheomalacia in eight
children. Granulation tissue developed over the stents in five of eight cases. Obstructing granulations were
removed by scraping or balloon compression in three and resulted in earlier than the planned removal in
two
Gallagher 2011 Non-controlled study. Authors retrospectively reviewed charts of 52 children with tracheomalacia and
treated with ipratropium bromide after having been referred for specialist care. Mild tracheomalacia was
diagnosed in 34 (65.3%) children while moderate tracheomalacia was seen in 18 (34.7%). Overall 32 (61.
5%) children had improvement in their symptoms following treatment with ipratropium bromide
McCarthy 1997 Non-controlled study. Twenty-four infants and children with various causes of airway obstruction including
tracheomalacia. Hospital mortality was 8.7%, 19 (79.2%) patients were alive and symptom-free. The single
most important predictor of mortality was the presence of associated cardiac anomalies
Nicolai 2001 Non-controlled study. Authors reported on 7 childrenwith extreme structural central airway obstruction (six
were mechanically ventilated). All patients showed marked improvement of their respiratory obstruction;
six were weaned at least temporarily from ventilation. Three children are well and at home
Vazquez-Jimenez 2001 Non-controlled study. Authors reported on 29 children operated for tracheomalacia associated with oe-
sophageal atresia. No early nor late mortality occurred. Surgery associated morbidity: reversible lesion of
the phrenic nerve was observed in two patients, a pneumothorax in three, and secondary wound healing
in one. In all but one patient symptoms improved markedly or disappeared within days or within the first
three months postoperatively. An increased susceptibility to respiratory infections was observed in long-
term follow-up of children
Vinograd 1994 Non-controlled study. Authors reported on surgical management (aortopexy) of 54 children with airway
problems, of whom 20 had tracheomalacia. No operative deaths occurred
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D A T A A N D A N A L Y S E S
Comparison 1. Human deoxyribonuclease versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Clinical failure (Number of
children with no significant
improvement in cough scores
at two weeks
1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
2 Daytime cough diary scores
(change from baseline)
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
3 Night time cough diary score
(change from baseline)
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
4 Daytime visual analogue score
(change from baseline)
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
5 Night time visual analogue score
(change from baseline)
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
6 Night time dyspnoea score
(change from baseline)
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
7 Difficulty expectorating sputum
score (change from baseline)
1 Std. Mean Difference (IV, Fixed, 95% CI) Totals not selected
8 Lung function: FVC% predicted 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
9 Lung function: FEV1 %
predicted
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
Analysis 1.1. Comparison 1 Human deoxyribonuclease versus placebo, Outcome 1 Clinical failure (Number
of children with no significant improvement in cough scores at two weeks.
Review: Interventions for primary (intrinsic) tracheomalacia in children
Comparison: 1 Human deoxyribonuclease versus placebo
Outcome: 1 Clinical failure (Number of children with no significant improvement in cough scores at two weeks
Study or subgroup rhDNase Placebo Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Boogaard 2009 11/17 12/21 1.38 [ 0.37, 5.14 ]
0.01 0.1 1 10 100
rhDNase Placebo
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Analysis 1.2. Comparison 1 Human deoxyribonuclease versus placebo, Outcome 2 Daytime cough diary
scores (change from baseline).
Review: Interventions for primary (intrinsic) tracheomalacia in children
Comparison: 1 Human deoxyribonuclease versus placebo
Outcome: 2 Daytime cough diary scores (change from baseline)
Study or subgroup rhDNase Placebo
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Boogaard 2009 17 -1 (1.6) 21 -1.7 (1.1) 0.70 [ -0.19, 1.59 ]
-4 -2 0 2 4
rhDNase Placebo
Analysis 1.3. Comparison 1 Human deoxyribonuclease versus placebo, Outcome 3 Night time cough diary
score (change from baseline).
Review: Interventions for primary (intrinsic) tracheomalacia in children
Comparison: 1 Human deoxyribonuclease versus placebo
Outcome: 3 Night time cough diary score (change from baseline)
Study or subgroup rhDNase Placebo
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Boogaard 2009 17 -0.7 (1.1) 21 -1.7 (1.5) 1.00 [ 0.17, 1.83 ]
-4 -2 0 2 4
rhDNase Placebo
21Interventions for primary (intrinsic) tracheomalacia in children (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 1.4. Comparison 1 Human deoxyribonuclease versus placebo, Outcome 4 Daytime visual analogue
score (change from baseline).
Review: Interventions for primary (intrinsic) tracheomalacia in children
Comparison: 1 Human deoxyribonuclease versus placebo
Outcome: 4 Daytime visual analogue score (change from baseline)
Study or subgroup rhDNase Placebo
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Boogaard 2009 17 -16.2 (36.4) 21 -31.9 (18.5) 15.70 [ -3.33, 34.73 ]
-50 -25 0 25 50
rhDNase Placebo
Analysis 1.5. Comparison 1 Human deoxyribonuclease versus placebo, Outcome 5 Night time visual
analogue score (change from baseline).
Review: Interventions for primary (intrinsic) tracheomalacia in children
Comparison: 1 Human deoxyribonuclease versus placebo
Outcome: 5 Night time visual analogue score (change from baseline)
Study or subgroup rhDNase Placebo
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Boogaard 2009 17 -13.7 (30.6) 21 -36.7 (29.1) 23.00 [ 3.86, 42.14 ]
-100 -50 0 50 100
rhDNase Placebo
22Interventions for primary (intrinsic) tracheomalacia in children (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 1.6. Comparison 1 Human deoxyribonuclease versus placebo, Outcome 6 Night time dyspnoea
score (change from baseline).
Review: Interventions for primary (intrinsic) tracheomalacia in children
Comparison: 1 Human deoxyribonuclease versus placebo
Outcome: 6 Night time dyspnoea score (change from baseline)
Study or subgroup rhDNase Placebo
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Boogaard 2009 17 -7.1 (18.5) 21 -19 (29.1) 11.90 [ -3.34, 27.14 ]
-100 -50 0 50 100
rhDNase Placebo
Analysis 1.7. Comparison 1 Human deoxyribonuclease versus placebo, Outcome 7 Difficulty expectorating
sputum score (change from baseline).
Review: Interventions for primary (intrinsic) tracheomalacia in children
Comparison: 1 Human deoxyribonuclease versus placebo
Outcome: 7 Difficulty expectorating sputum score (change from baseline)
Study or subgroup rhDNase Placebo
Std.
Mean
Difference
Std.
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Boogaard 2009 17 -20.8 (29.8) 21 -35.6 (33.1) 0.46 [ -0.19, 1.11 ]
-100 -50 0 50 100
rhDNase Placebo
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Analysis 1.8. Comparison 1 Human deoxyribonuclease versus placebo, Outcome 8 Lung function: FVC %
predicted.
Review: Interventions for primary (intrinsic) tracheomalacia in children
Comparison: 1 Human deoxyribonuclease versus placebo
Outcome: 8 Lung function: FVC % predicted
Study or subgroup rhDNase Placebo
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Boogaard 2009 14 0.6 (13.8) 13 -8.2 (9.4) 8.80 [ -0.05, 17.65 ]
-100 -50 0 50 100
rhDNase Placebo
Analysis 1.9. Comparison 1 Human deoxyribonuclease versus placebo, Outcome 9 Lung function: FEV1 %
predicted.
Review: Interventions for primary (intrinsic) tracheomalacia in children
Comparison: 1 Human deoxyribonuclease versus placebo
Outcome: 9 Lung function: FEV1 % predicted
Study or subgroup rhDNase Placebo
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Boogaard 2009 14 -1.6 (14.1) 13 -10.8 (11.7) 9.20 [ -0.55, 18.95 ]
-100 -50 0 50 100
rhDNase Placebo
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A P P E N D I C E S
Appendix 1. CENTRAL search strategy (the Cochrane Library)
#1MeSH descriptor Tracheal Diseases explode all trees with qualifiers: DT,SU,TH
#2MeSH descriptor Trachea explode all trees with qualifiers: AB,SU
#3MeSH descriptor Bronchi explode all trees with qualifiers: AB,SU
#4tracheomalac*
#5tracheo-malac*
#6trache* near malac*
#7malacia*
#8trache* near abnormal*
#9(#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8)
Appendix 2. MEDLINE search strategy (Ovid)
Topic search
1. tracheomalacia$.mp.
2. tracheo-malac$.mp.
3. (trache$ adj5 malac$).mp.
4. malacia$.mp.
5. exp Tracheal Diseases/dt, su, th [Drug Therapy, Surgery, Therapy]
6. exp TRACHEA/ab, su [Abnormalities, Surgery]
7. exp BRONCHI/ab [Abnormalities]
8. (trache$ adj5 abnormal$).mp.
9. or/1-8
10. ADOLESCENT/ or exp CHILD/ or exp INFANT/ or exp PEDIATRICS/
11. (child$ or paediat$ or pediat$ or adolesc$ or infan$ or toddler$ or bab$ or young$ or preschool$ or pre school$ or pre-school$ or
newborn$ or new born$ or new-born$ or neo-nat$ or neonat$).mp.
12. 10 or 11
13. 9 and 12
RCT filter
1. exp “clinical trial [publication type]”/
2. (randomised or randomised).ab,ti.
3. placebo.ab,ti.
4. dt.fs.
5. randomly.ab,ti.
6. trial.ab,ti.
7. groups.ab,ti.
8. or/1-7
9. Animals/
10. Humans/
11. 9 not (9 and 10)
12. 8 not 11
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Appendix 3. EMBASE search strategy (Ovid)
Topic search
1. tracheomalac$.mp.
2. tracheo-malac$.mp.
3. (trache$ adj5 malac$).mp.
4. malacia$.mp.
5. (trache$ adj5 abnormal$).mp.
6. exp TRACHEOMALACIA/
7. or/1-6
8. exp pediatrics/
9. exp CHILD/ or exp INFANT/ or exp ADOLESCENT/
10. (child$ or paediat$ or pediat$ or adolesc$ or infan$ or toddler$ or bab$ or young$ or preschool$ or pre school$ or pre-school$ or
newborn$ or new born$ or new-born$ or neo-nat$ or neonat$).mp.
11. 8 or 9 or 10
12. 7 and 11
RCT filter
1. Randomized Controlled Trial/
2. randomisation/
3. Controlled Study/
4. Clinical Trial/
5. controlled clinical trial/
6. Double Blind Procedure/
7. Single Blind Procedure/
8. Crossover Procedure/
9. or/1-8
10. (clinica$ adj3 trial$).mp.
11. ((singl$ or doubl$ or trebl$ or tripl$) adj3 (mask$ or blind$ or method$)).mp.
12. exp Placebo/
13. placebo$.mp.
14. random$.mp.
15. ((control$ or prospectiv$) adj3 (trial$ or method$ or stud$)).mp.
16. (crossover$ or cross-over$).mp.
17. or/10-16
18. 9 or 17
19. exp ANIMAL/
20. Nonhuman/
21. Human/
22. 19 or 20
23. 22 not 21
24. 18 not 23
WH A T ’ S N E W
Last assessed as up-to-date: 8 March 2012.
26Interventions for primary (intrinsic) tracheomalacia in children (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Date Event Description
8 March 2012 New citation required and conclusions have changed One randomised controlled trial (RCT) identified and
added to the review. We added a summary of findings table
and updated the text including the plain language summary
and background
8 March 2012 New search has been performed New literature search run
H I S T O R Y
Protocol first published: Issue 2, 2005
Review first published: Issue 4, 2005
Date Event Description
7 April 2008 Amended Converted to new review format.
25 July 2005 New citation required and conclusions have changed Substantive amendment
C O N T R I B U T I O N S O F A U T H O R S
IBM: formulation and writing of protocol.
AC: initiation, formulation and writing of protocol, review and selection of studies from the search, data extraction and writing and
updating the review.
VG: updated the review, entered data in the updated review and contacted the original investigator of the included study for raw data.
D E C L A R A T I O N S O F I N T E R E S T
None known.
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S O U R C E S O F S U P P O R T
Internal sources
• Royal CHildren’s Hospital Foundation, Australia.
Program grant awarded by the Queensland Children’s Medical Research Institute
External sources
• National Health and Medical Research Council, Australia.
Fellowship to AC (grant number 545216)
• Centre of Research Excellence in Lung Health of Aboriginal and Torres Strait Islander Children, Australia.
NHMRC grant number 1040830
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
The inclusion criteria was children under 15 years old with tracheomalacia, but we included a trial in which the oldest child enrolled
was 15.5 years (Boogaard 2009).
I N D E X T E R M S
Medical Subject Headings (MeSH)
Trachea [∗abnormalities]; Tracheal Diseases [∗therapy]
MeSH check words
Adolescent; Child; Humans
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